Fierce Pharma April 15, 2024
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy.
Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products.
At the top, Pfizer ceded the No. 1 slot as its revenue tumbled 41% from an industry record $100.3 billion in 2022 to $58.5 billion last year. The difference was directly attributable to declining sales of COVID vaccine Comirnaty and COVID antiviral Paxlovid. After the duo combined for sales of $56.7 billion in...
Today's Sponsors
Today's Sponsor